EP1490078A1 - Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450 - Google Patents
Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450Info
- Publication number
- EP1490078A1 EP1490078A1 EP02716955A EP02716955A EP1490078A1 EP 1490078 A1 EP1490078 A1 EP 1490078A1 EP 02716955 A EP02716955 A EP 02716955A EP 02716955 A EP02716955 A EP 02716955A EP 1490078 A1 EP1490078 A1 EP 1490078A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- drugs
- extract
- liver
- hepatotoxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 231100000304 hepatotoxicity Toxicity 0.000 title claims abstract description 46
- 235000015489 Emblica officinalis Nutrition 0.000 title claims abstract description 41
- 240000009120 Phyllanthus emblica Species 0.000 title claims abstract description 41
- 206010019851 Hepatotoxicity Diseases 0.000 title claims abstract description 36
- 230000007686 hepatotoxicity Effects 0.000 title claims abstract description 36
- 230000001801 hepatocurative effect Effects 0.000 title claims abstract description 26
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 54
- 239000000284 extract Substances 0.000 claims abstract description 44
- 239000000654 additive Substances 0.000 claims abstract description 20
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 26
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 26
- 229960001225 rifampicin Drugs 0.000 claims description 26
- 229960003350 isoniazid Drugs 0.000 claims description 24
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 21
- 210000004185 liver Anatomy 0.000 claims description 19
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 18
- 229960005206 pyrazinamide Drugs 0.000 claims description 18
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 claims description 16
- 210000003494 hepatocyte Anatomy 0.000 claims description 12
- 208000019423 liver disease Diseases 0.000 claims description 12
- 230000003908 liver function Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 210000005229 liver cell Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 230000003859 lipid peroxidation Effects 0.000 claims description 8
- 230000002301 combined effect Effects 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 229960005489 paracetamol Drugs 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 235000011869 dried fruits Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 231100000234 hepatic damage Toxicity 0.000 claims description 4
- 230000008818 liver damage Effects 0.000 claims description 4
- 230000005976 liver dysfunction Effects 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 231100000989 no adverse effect Toxicity 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 description 25
- 231100000419 toxicity Toxicity 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 15
- 230000007056 liver toxicity Effects 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002443 hepatoprotective effect Effects 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 231100000025 genetic toxicology Toxicity 0.000 description 7
- 230000001738 genotoxic effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000007541 cellular toxicity Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004264 monolayer culture Methods 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000002032 cellular defenses Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001093575 Alma Species 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001358279 Malaya Species 0.000 description 1
- IYMHVUYNBVWXKH-ZITZVVOASA-N Pedunculagin Chemical compound C([C@H]1OC2O)OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]1[C@H]1[C@H]2OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C=C2C(=O)O1 IYMHVUYNBVWXKH-ZITZVVOASA-N 0.000 description 1
- HVXQPVRDPFKKHP-UHFFFAOYSA-N Pedunculagin Natural products OC1C2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c(O)cc4C(=O)OC(O2)C5OC(=O)c6cc(O)c(O)c(O)c6c7c(O)c(O)c(O)cc7C(=O)OC15 HVXQPVRDPFKKHP-UHFFFAOYSA-N 0.000 description 1
- 229920000158 Pedunculagin Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710199886 Protein 0.5 Proteins 0.000 description 1
- MTFGSHWJTZMFBZ-UHFFFAOYSA-N Punigluconin Natural products OC(C(OC(=O)c1cc(O)c(O)c(O)c1)C(=O)O)C2OC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c(O)cc4C(=O)OCC2O MTFGSHWJTZMFBZ-UHFFFAOYSA-N 0.000 description 1
- 229920000319 Punigluconin Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- UEHSSTYZXFBDNL-DNOBIOAJSA-N [(10R,15R)-3,4,5,21,22,23-hexahydroxy-8,13,18-trioxo-12-(3,4,5-trihydroxybenzoyl)oxy-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,11,19,21-heptaen-11-yl] 3,4,5-trihydroxybenzoate Chemical compound Oc1cc(cc(O)c1O)C(=O)OC1=C(OC(=O)c2cc(O)c(O)c(O)c2)C(=O)O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(O)c(O)c(O)cc3C(=O)O[C@@H]12 UEHSSTYZXFBDNL-DNOBIOAJSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001043 anti-lipoperoxidant effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124976 antitubercular drug Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- GDVRUDXLQBVIKP-UHFFFAOYSA-N beta-D-glucogallin Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000505 clastogenic Toxicity 0.000 description 1
- 230000003541 clastogenic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- UEHSSTYZXFBDNL-UHFFFAOYSA-N emblicanin-A Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OCC3OC(=O)C=2OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 UEHSSTYZXFBDNL-UHFFFAOYSA-N 0.000 description 1
- SVYWZVZMBHFNGC-UHFFFAOYSA-N emblicanin-B Natural products OC1C(O)C(=O)OC1C(C(O)=O)OC(=O)C1=CC(O)=C(O)C(O)=C1 SVYWZVZMBHFNGC-UHFFFAOYSA-N 0.000 description 1
- 239000002375 environmental carcinogen Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- -1 oxy radicals Chemical class 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- IYMHVUYNBVWXKH-UHFFFAOYSA-N pedunculagin I isomer Natural products OC1OC2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C2C1OC(=O)C1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(O)C=C1C(=O)O2 IYMHVUYNBVWXKH-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- KZEYIYXACMUTRM-WIMKJKQSSA-N punigluconin Chemical compound O([C@@H]([C@@H]1OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C=C2C(=O)OC[C@H]1O)[C@@H](OC(=O)C=1C=C(O)C(O)=C(O)C=1)C(O)=O)C(=O)C1=CC(O)=C(O)C(O)=C1 KZEYIYXACMUTRM-WIMKJKQSSA-N 0.000 description 1
- 229940049414 pyrazinamide and isoniazid rifampicin Drugs 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
- liver diseases As one among six thrust areas for multidisciplinary study.
- liver cirrhosis as such accounts amongst the ten top fatal diseases in the world. Exposure of humans to a variety of agents such as chemicals and drugs (xenobiotics), many natural compounds, viral and bacterial pathogens with attendant predisposable conditions, etc. are considered responsible for hepatic insufficiency.
- liver toxicity There are large group of drugs which on repeated administration produce liver toxicity. These are mediated primarily by bioactivation so that the products of parent drug are toxic. Another class of drugs induce toxicity by causing membrane rupture or DNA damage and by interfering with protein synthesis. One of the important categories of drugs are the anti-TB drugs which when taken regularly cause hepatotoxicity.
- Tuberculosis is prevelent in all counteries of the world - tropical, subtropical and colder regions.
- the chemotherapy of tuberculosis is important and challenging, because the disease is often chronic and the toxicity due to anti-TB drugs pose therapeutic problems.
- the disorders of the liver caused during the treatment of tuberculosis, by known antimicrobial agents range from jaundice to the fibrosis of the liver.
- Three drugs i.e., rifampicin, pyrazinamide and isoniazid comprise first choice treatment of tuberculosis. These are to be administered for long period of time and produce liver dysfunction leading to toxicity.
- Emblica officinalis Gaertn. (Hindi : Amla) (Euphorbiaceae)is widespread in India, Ceylon,Malaya and China. The tree is common in mixed deciduous forests of India ascending to4500 ft on the hills , cultivated in gardens and homeyards. It is a small or medium sized deciduous tree, fruits depressed globose, Vi to 1 inch in diameter, fleshy, and contains six trigonows seeds. The fruit is sour and is occasionally eaten raw.
- the fruit pulp contains (%) ; moistre 81.2, protein 0.5, fat 0.1, mineral matter 0.7, Ca 0.005, Phosphorus 0.02 and Iron 1.2 mg 100 gm, nicotinic acid 0.2 mg/100 gm, vitamin C 600 mg/100 mg.
- moistre 81.2 protein 0.5, fat 0.1, mineral matter 0.7, Ca 0.005, Phosphorus 0.02 and Iron 1.2 mg 100 gm, nicotinic acid 0.2 mg/100 gm, vitamin C 600 mg/100 mg.
- the potent vitamin C-like activity has been located in the low molecular weight hydrolysable tannins.
- Four such compounds emblicanin-A, emblicanin-B, punigluconin and pedunculagin have been isolated from the fresh pericarp.
- the first two compounds are naturally occurring galloellagi-tannins ( Ghosal, et al, IndJChem, 1996:353 :941-948; Bhattacharya et al, Phytomedicine, 2000: 7: 173-175).
- the fruit is acrid, cooling, and diuretic. Dried fruit is useful in haemorrhage, diarrhoea and dysentry. It has been extensively use in anemia, liver diseases and dyspepsea. A fermented liquor prepared from the fruits is used in jaundice. Fruits are a reputed Ayurvedic rasayan (revitaliser, biological response modifier) (SharmaPN. Dravyaguna vijnana, Chaukhamba Sanskrit Sansthan, Naranasi, 1978). Several pharmacological properties are also reported.
- Leaf extracts have been found to be anti-inflammatory (Summanen et al, Planta Medica, 1993:59: 666), antioxidant (Jose.and Kuttan, Clin. Biochem. ⁇ utr, 1995:19:63-70), hypolipidemic (Mathw:eta ⁇ ,JEthnopharmacol, 1996:50 :61-68), cell growth inhibition (Psatima et al, ACS Symp. Ser, 1998, p701). Hepatoprotective activity of Emblica officinalis extracts against a chemical viz., carbon tetrachoride induced liver toxicity has been demonstrated ( Jose JK & Kutten R, J.
- the Applicants provide protection against hepatotoxicity produced by all such drugs, which are bio-activated by multiple CYP isoforms as indicated by clinical parameters in serum/liver.
- clinical parameters showing toxicity are reversed even if the symptoms of genotoxicity may not begin to appear.
- decrease in abnormal rise of serum Bilirubin which may be attributed to a protective effect also due to other cellular factors such as membrane stabilization, as revealed in primary monolayer cultures of liver cells.
- preparations from Emblica officinalis which are superior so far as their systemic effects are manifested in clinical profile (serum/liver parameters) which correlate to their hepatoprotective profile.
- the main object of the present invention is to develop a hepatocurative composition against CYP 450 bio-activation hepatotoxicity induced by drugs.
- Another main object of the present invention is to develop a hepatocurative composition against CYP 450 bio-activation hepatotoxicity induced by anti-TB drugs.
- Still another object of the present invention is to develop a use of preparing an extract from fruit Emblica officinalis.
- Still another object of the present invention is to develop a use for treating a subject for CYP 450 and free radical mediated hepatotoxicity caused by drugs using composition comprising an extract from Emblica officinalis.
- Still another object of the present invention is to develop a use of using hepatocytes to understand the effect of extract from fruit Emblica officinalis.
- composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
- the present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
- composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives.
- additives are selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and or pharmaceutically acceptable carrier, excipient, diluent, or solvent.
- composition is administered orally.
- extract and additives are in the ratio ranging between 1 : 1 to 1:10.
- said additives have no effect on the hepatocurative effect of the said extract.
- said extract is prepared in a solvent selected from a group comprising aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents.
- composition shows tanin content in the range of 8.5 to 15%.
- composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
- composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives, said use comprising steps of adding polar solvent to the fruit Emblica Officinalis to obtain the extract and optionally adding pharmaceutically acceptable additives.
- composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
- composition is not effective against hepatotoxicity which is independent of bio-activation by CYP 450.
- composition is administered orally.
- said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
- said composition is useful for treating animals or human beings.
- said drugs are selected from a group comprising Paracetamol, CC1 4 , and anti-TB drugs.
- anti-TB drugs are selected from a group comprising Rifampicin, Pyrazinamide, and isoniazid.
- composition controls abnormal rise in the clinical pathological symptoms revealed by serum/liver markers serving as indices of hepatic damage besides control of high levels of Bilirubin.
- said drugs is used at cytotoxic levels to produce valid and reproducible results in liver cells.
- said composition is useful for treating animals or human beings.
- said composition has no adverse effect on health.
- composition shows restoration of hepatocyte viability.
- composition reverses the leakage of glutamate pyruvate transaminase (GPT) from hepatocyte.
- GPT glutamate pyruvate transaminase
- composition shows hepatocurative effect of about 96% against combined effect of anti-TB drugs of Rifampicin, isoniazid, and pyrazinamide.
- composition shows about 94%) hepatocurative effect against rise in lipid Peroxidation (LPO) induced by combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
- LPO lipid Peroxidation
- composition shows about 96% decrease of serum Bilirubin as a hepatocurative effect against combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
- dosage of said composition is ranging between 50-250 mg/kg.
- the applicants provide protection against hepatotoxicity produced by all drugs, which are bio-activated by multiple CYP isoforms as indicated by clinical parameters in serum/hver. Besides, we claim that the clinical parameters showing toxicity are reversed even if the symptoms of genotoxicity may not begin to appear. For example decrease in abnormal rise of serum Bilirubin, which may be attributed to a protective effect also due to other cellular factors such as membrane stabilization, as revealed in primary monolayer cultures of liver cells.
- Emblica Officinalis cures hepatotoxicity induced by drugs that is restricted to CYP 450 bio- activation hepatotoxicity.
- compositions and methods of the present invention increase biological defence mechanism of the tissue, improve recovery from dysfunctional states of the liver after prolonged challenge of anti-TB drugs.
- compositions and use of the present invention contain one of the extracts/ fractions of Emblica officinalis fruit as an essential ingredient. These extracts/ fractions may be obtained from fresh or semi dried fruits of Emblica officinalis.
- the compositions are formulated with more than one extracts and combined in any weight ratios. The preferred weight ratios include 1:1,1:2,1:1:1:, 1:2:2.2:1:2:, 2:2:1.
- the present invention is related to preparation and use of products from Emblica officinalis, which restores normal liver function against drug induced toxicity caused as a result of bio-activation of drugs applicable with particular relevance to anti-TB drug(s) induced liver toxicity.
- the products of the invention comprise aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents extracts/ fractions from Emblica officinalis, obtained either from fresh or semi-dried fruits. These contain 8.5 -15 % of tannin content. It also relates to preparation of compositions of such products in different proportions of more than one ingredient.
- liver cell (hepatocyte) cultures which ideally provide an insight into the mechanism of a toxin-induced impairment of hepato-biliary dysfunction because this model allows use of a test compounds (such as anti-TB drugs) to be used at cytotoxic level so that a valid and reproducible toxicity is generated.
- test compounds such as anti-TB drugs
- the in vitro cell culture model is of significant interest in ascertaining the mechanisms of toxicity and its reversal by protective agents.
- liver cells are considered as system of choice which have found ample application in the evaluation of cyto- cum geno-toxicity of chemicals and drugs (Nakagawa and Tayama, Arch Toxicol, 1995:69:208) and as such have been used in the evaluation of hepatoprotective profiles of the present invention.
- the mechanisms are revealed in critical biochemical functions of liver cells which are sensitive indicators of drug (s) toxicity. (Tomasi et al, Toxicol /Ntf/zo/: 15: 178-183).
- the preparations act in a specific manner. These act against toxicity produced by drugs including anti-TB drugs which require bioactivation by hepatic cytochrome P 450 dependent mixed function oxidases. Cytochrome P450 have been shown to be involved in the liver toxicity (Anundi I, Lindros KO, Pharmacol Toxicol 1992; 70;453-458). Participation of CYP 450 dependent oxidation of drugs including anti-tubercular drugs rifampicin, isoniazid, pyrazinamide in liver is reported ( Ono et al, Biol Pharm Bull 1998:21 :421-425).
- the metabolic activation of drugs including anti-TB drugs alone or in combination is also accompanied by reactive intermediates which may be free radical/ active metabolites/ free oxy radicals through a variety of cellular oxidative metabolic pathways.
- Figure 1 shows liver toxicity wherein plant extract attenuates Rifampicin induced hepatotoxicity by restoring liver function to normal (95% effect).
- the cell toxicity indicators shown in the said Fig. 1 is the leakage of lactate dehydrogenase (LDH) from intact cells after toxin challenge and its reversal by extracts.
- LDH lactate dehydrogenase
- Figure 2 shows leakage of glutamate pyruvate transaminase wherein said plant extracts in combination attenuates Rifampicin + isoniazid induced hepatotoxicity by restoring liver function to normal (96%).
- the cell toxicity indicators shown in Fig 2 is the leakage of glutamate pyruvate transaminase (GPT) from intact cells after toxin challenge and its reversal by the extracts in combination. (Model: primary monolayer cultures of liver cells).
- FIG. 3 shows leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by Emblica officinalis fraction wherein Emblica officinalis reverses Rifampicin + isoniazid +pyrazinamide induced hepatotoxicity and restores the liver function to normal
- the cell toxicity indicators shown in Fig 3 is the leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by Emblica officinalis fraction.
- GPT serum glutamate pyruvate transminase
- Figure 4 shows protection against cell leakage wherein, Emblica officinalis fractions in combination prevents Rifampicin + isoniazid induced toxicity.
- Fig. 4 shows that fractions provide 96% protection against cell leakage as measured by serum GPT levels and increases cellular defense. 75% increase in glutathione levels (liver) is observed.
- Figure 5 shows Emblica officinalis extract reverses Rifampicin + isoniazid + pyrazinamide induced toxicity.
- Fig 5 shows 94 % protection against rise in lipid Peroxidation
- Figure 6 shows a flow chart for the preparation of extract from fruit Emblica Officinalis.
- Table 1 shows that the plant products are effective against paracetamol hepatotoxicity which is mainly dependent against bioactivation mechanisms mediated by CYP 450. % protection is shown as combined effect release of LDH and GPT in serum.
- Table 2 shows that the preparations of the present invention are not effective against liver toxicity produced by agents where the toxicity is primarily not dependent on bioactivation by
- CYP 450 Table 2: Effect of plant products against hepatotoxicity produced by galactosamine.
- Fig. 1 The cell toxicity indicators shown in Fig. 1 is the leakage of lactate dehydrogenase (LDH) from intact cells after toxin challenge and its reversal by extracts. (Model; primary monolayer cultures of liver cells)
- LDH lactate dehydrogenase
- Plant extracts in combination attenuates Rifampicin + isoniazid induced hepatotoxicity by restoring liver function to normal (96%).
- the cell toxicity indicators shown in Fig 2 is the leakage of glutamate pyruvate tiansaminase (GPT) from intact cells after toxin challenge and its reversal by the extracts in combination. (Model: primary monolayer cultures of liver cells).
- Emblica officinalis reverses Rifampicin + isoniazid +pyrazinamide induced hepatotoxicity and restores the liver function to normal (96%).
- the cell toxicity indicators shown in Fig 3 is the leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by
- Emblica officinalis fractions in combination prevents Rifampicin + isoniazid induced toxicity.
- Fig. 4 shows that fractions provide 96% protection against cell leakage as measured by serum GPT levels and increases cellular defense. 75% increase in glutathione levels (liver) is observed.
- Emblica officinalis extract reverses Rifampicin + isoniazid + pyrazinamide induced toxicity.
- Fig 5 shows 94 % protection against rise in lipid Peroxidation (LPO, liver) and 96% decrease of serum Bilirubin in response to treatment with extract of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.
Description
HEPATOCURATIVE EFFECT OF EMB ICA OFFICINA IS ON HEPATOTOXICITY RELATED TO CYTOCHRO E P-450
Field of the present invention The present invention relates to a composition useful for hepatocurative effect against CYP
450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
Background of the present invention Liver disorders are still the major health hazards both in urban and rural areas of the world.
Despite scientific advances in our understanding of hepatotoxicity, and leads provided by traditional system of medicine, we do not have yet any effective entities to cure liver derangement more importantly those which are caused by a variety of drugs. The Indian Council of Medical Research, New Delhi in its revised research programme on traditional medicines, has adopted liver diseases as one among six thrust areas for multidisciplinary study.
The disorders of the liver may be classified into acute or chronic hepatitis (inflammatory liver diseases), hepatosis (non-inflammatory disorders). The acute condition is often followed by liver cirrhosis as well as hepatic coma with grave prognosis. Liver cirrhosis as such accounts amongst the ten top fatal diseases in the world. Exposure of humans to a variety of agents such as chemicals and drugs (xenobiotics), many natural compounds, viral and bacterial pathogens with attendant predisposable conditions, etc. are considered responsible for hepatic insufficiency.
There are large group of drugs which on repeated administration produce liver toxicity. These are mediated primarily by bioactivation so that the products of parent drug are toxic. Another class of drugs induce toxicity by causing membrane rupture or DNA damage and by interfering with protein synthesis. One of the important categories of drugs are the anti-TB drugs which when taken regularly cause hepatotoxicity.
Tuberculosis is prevelent in all counteries of the world - tropical, subtropical and colder regions. The chemotherapy of tuberculosis is important and challenging, because the disease is often chronic and the toxicity due to anti-TB drugs pose therapeutic problems. The disorders of the liver caused during the treatment of tuberculosis, by known antimicrobial agents range from jaundice to the fibrosis of the liver. Several cases progress to the chronic form of disease or have a fulminant course and prove fatal. Three drugs i.e., rifampicin, pyrazinamide and isoniazid comprise first choice treatment of tuberculosis. These are to be administered for long period of time and produce liver dysfunction leading to toxicity.
Jaundice is amongst the most prominent incidence of their adverse raections. The characteristic pathology is the bridging and multilobular necrosis. Hypersensitivity to these drugs leads to hepatitis. Multidrug treatment also poses special problems. Rifampicin causes liver damage. Disturbances in liver function is more if it is combined with isoniazid. Pyrazinamide is the most toxic of the three anti-TB drugs. Continuation of the drugs in combination after symptoms of hepatic dysfunction have appeared tends to increase further the severity of damage. Severe hepatic injury leading to death has been reported in patients receiving these drugs (Slivka, IL, Farmakol Toksikol-1989: 52;82-85)
In our traditional system of medicines (Ayurveda), use of several medicinal plants have been prescribed for alleviating liver disorders. There are nearly forty indigenous polyherbal formulations from more than 100 plants enjoying reputation of being hepatoprotectives. However , none have been specified as a therapeutic agent, which is able to protect the liver from injury due to treatment of anti - TB drugs. This owes partly to the fact that reports are scanty with regard to evaluation of plants / plant products, which would seem focussed specially against hepatic injury caused by drugs which produce toxicity as a result of bioactivation.
There is thus a growing interest in the development of herbal entities considered relatively safe for alleviating liver disorders specifically caused by the anti - TB drugs. Emblica officinalis Gaertn. (Hindi : Amla) (Euphorbiaceae)is widespread in India, Ceylon,Malaya and China. The tree is common in mixed deciduous forests of India ascending to4500 ft on the hills , cultivated in gardens and homeyards. It is a small or medium sized deciduous tree, fruits depressed globose, Vi to 1 inch in diameter, fleshy, and contains six trigonows seeds. The fruit is sour and is occasionally eaten raw. The fruit pulp contains (%) ; moistre 81.2, protein 0.5, fat 0.1, mineral matter 0.7, Ca 0.005, Phosphorus 0.02 and Iron 1.2 mg 100 gm, nicotinic acid 0.2 mg/100 gm, vitamin C 600 mg/100 mg. (Medicinal plants of India, Satyavati et al (ed.), ICMR, new Delhi, 1976, p 377). The potent vitamin C-like activity has been located in the low molecular weight hydrolysable tannins. Four such compounds emblicanin-A, emblicanin-B, punigluconin and pedunculagin have been isolated from the fresh pericarp. The first two compounds are naturally occurring galloellagi-tannins ( Ghosal, et al, IndJChem, 1996:353 :941-948; Bhattacharya et al, Phytomedicine, 2000: 7: 173-175).
The fruit is acrid, cooling, and diuretic. Dried fruit is useful in haemorrhage, diarrhoea and dysentry. It has been extensively use in anemia, liver diseases and dyspepsea. A fermented liquor prepared from the fruits is used in jaundice. Fruits are a reputed Ayurvedic rasayan (revitaliser, biological response modifier) (SharmaPN. Dravyaguna vijnana, Chaukhamba
Sanskrit Sansthan, Naranasi, 1978). Several pharmacological properties are also reported. Leaf extracts have been found to be anti-inflammatory (Summanen et al, Planta Medica, 1993:59: 666), antioxidant (Jose.and Kuttan, Clin. Biochem. Νutr, 1995:19:63-70), hypolipidemic (Mathw:eta\,JEthnopharmacol, 1996:50 :61-68), cell growth inhibition (Psatima et al, ACS Symp. Ser, 1998, p701). Hepatoprotective activity of Emblica officinalis extracts against a chemical viz., carbon tetrachoride induced liver toxicity has been demonstrated ( Jose JK & Kutten R, J. Ethnopharmacology 2000:72; 135-40; Bhattacharya et al, Phytomerdicine 2000:7: 173-5). The article by Sharma et al (Hum Exp. toxicol 2000:19; 337-84) suggests that Emblica Officinalis prevents genotoxicity induced by benzopyrines. Benzopyrene is one of the prominent environmental carcinogen which is a specific substrate for CYP 450 1A1. Both are clastogenic. However, the liver toxicity produced by the drugs including anti-TB drugs is dependent on a great measure to their bio-activation through multiple CYP isoforms, the most prominent being CYP450 3A4. There are several agents, which reduce CYP levels or reverse the micronuclei formation but are not hepatoprotective. To cite an example, applicants have developed a molecule, pipeline which is a specific inhibitor of CYP 450 1A1, but is not hepatoprotective. Similarly, there are several known compounds, which reverse the genotoxicity but are not hepatoprotective. Therefore the decrease in CYP 1 Al or reversal of clastrogencity can not be construed as hepatoprotection. For example, jaundice (hepato-biliary dysfunction) has not been correlated with genotoxicity, rather it may be an early event in the onset of liver toxicity. In the present article, a casual relationship between CYP decrease or genotoxicity has not been related to attenuation of clinical pathology usually seen in symptoms of hepatotoxicity.
In the present invention, the Applicants provide protection against hepatotoxicity produced by all such drugs, which are bio-activated by multiple CYP isoforms as indicated by clinical parameters in serum/liver. Besides, we claim that the clinical parameters showing toxicity are reversed even if the symptoms of genotoxicity may not begin to appear. For example decrease in abnormal rise of serum Bilirubin, which may be attributed to a protective effect also due to other cellular factors such as membrane stabilization, as revealed in primary monolayer cultures of liver cells. Thus, we claim preparations from Emblica officinalis which are superior so far as their systemic effects are manifested in clinical profile (serum/liver parameters) which correlate to their hepatoprotective profile.
Object of the present invention
The main object of the present invention is to develop a hepatocurative composition against CYP 450 bio-activation hepatotoxicity induced by drugs.
Another main object of the present invention is to develop a hepatocurative composition against CYP 450 bio-activation hepatotoxicity induced by anti-TB drugs.
Yet another object of the present invention is to develop a composition from fruit Emblica officinalis for hepatocurative effect. Still another object of the present invention is to develop a composition from fruit Emblica officinalis for hepatocurative effect against CYP 450 bio-activation hepatotoxicity.
Still another object of the present invention is to develop a use of preparing an extract from fruit Emblica officinalis.
Still another object of the present invention is to develop a use for treating a subject for CYP 450 and free radical mediated hepatotoxicity caused by drugs using composition comprising an extract from Emblica officinalis.
Still another object of the present invention is to develop a use of using hepatocytes to understand the effect of extract from fruit Emblica officinalis.
Summary of the invention The present invention relates to a composition useful for hepatocurative effect against CYP
450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
Detailed description of the present invention Accordingly, the present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and use of treating drug induced hepatotoxicity.
In one embodiment of the present invention, a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives.
In another embodiment of the present invention, wherein said additives are selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and or pharmaceutically acceptable carrier, excipient, diluent, or solvent.
In yet another embodiment of the present invention, wherein said composition is administered orally.
In still another embodiment of the present invention, wherein said extract and additives are in the ratio ranging between 1 : 1 to 1:10.
In still another embodiment of the present invention, wherein said additives have no effect on the hepatocurative effect of the said extract. In still another embodiment of the present invention, wherein said extract is prepared in a solvent selected from a group comprising aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents.
In still another embodiment of the present invention, wherein said composition shows tanin content in the range of 8.5 to 15%. In still another embodiment of the present invention, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
In further another embodiment of the present invention, a use of preparing composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives, said use comprising steps of adding polar solvent to the fruit Emblica Officinalis to obtain the extract and optionally adding pharmaceutically acceptable additives.
In another embodiment of the present invention, wherein said fruit is incubated with polar solvent at room temperature for about 15-25 hours. hi yet another embodiment of the present invention, wherein said extract is from fresh and/or semi dried fruits of Emblica Officinalis.
In still another embodiment of the present invention, wherein said extract and additives are in the ratio ranging between 1 : 1 to 1 : 10.
In still another embodiment of the present invention, wherein said extract is prepared in a solvent selected from a group comprising aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents.
In still another embodiment of the present invention, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
In further embodiment of the present invention, a use of treating a subject for CYP 450 and free radical mediated hepatotoxicity caused by drugs using composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives.
In another embodiment of the present invention, introducing drug toxicity in hepatocytes.
In yet another embodiment of the present invention, adding said composition to said hepatocytes exposed to drug hepatotoxicity.
In still another embodiment of the present invention, measuring changes in the level of liver/serum markers to estimate hepatocurative effect of the said composition.
In still another embodiment of the present invention, wherein said use is particularly effective against hepatotoxicity caused by anti-TB drugs.
In still another embodiment of the present invention, wherein said composition is not effective against hepatotoxicity which is independent of bio-activation by CYP 450. In still another embodiment of the present invention, wherein said composition is administered orally.
In still another embodiment of the present invention, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads. In still another embodiment of the present invention, wherein said composition is useful for treating animals or human beings.
In still another embodiment of the present invention, wherein said composition has no adverse effect on health.
In still another embodiment of the present invention, wherein said drugs are selected from a group comprising Paracetamol, CC14, and anti-TB drugs.
In still another embodiment of the present invention, wherein said anti-TB drugs are selected from a group comprising Rifampicin, Pyrazinamide, and isoniazid.
In still another embodiment of the present invention, wherein said composition controls abnormal rise in the clinical pathological symptoms revealed by serum/liver markers serving as indices of hepatic damage besides control of high levels of Bilirubin.
In still another embodiment of the present invention, wherein said use uses hepatocyte culture for ideal insight.
In still another embodiment of the present invention, wherein said drugs is used at cytotoxic levels to produce valid and reproducible results in liver cells. In still another embodiment of the present invention, wherein said composition is useful for treating animals or human beings.
In still another embodiment of the present invention, wherein said composition has no adverse effect on health.
In still another embodiment of the present invention, wherein said composition shows restoration of hepatocyte viability.
In still another embodiment of the present invention, wherein said use shows prevention of cell membrane leakage. h still another embodiment of the present invention, wherein said composition shows about 96% hepatocurative effect against combined effect of anti-TB drugs of Rifampicin, and Isoniazid.
In still another embodiment of the present invention, wherein said composition reverses the leakage of glutamate pyruvate transaminase (GPT) from hepatocyte.
In still another embodiment of the present invention, wherein said composition shows hepatocurative effect of about 96% against combined effect of anti-TB drugs of Rifampicin, isoniazid, and pyrazinamide.
In still another embodiment of the present invention, wherein said composition shows about 94%) hepatocurative effect against rise in lipid Peroxidation (LPO) induced by combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
In still another embodiment of the present invention, wherein said composition shows about 96% decrease of serum Bilirubin as a hepatocurative effect against combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
In still another embodiment of the present invention, wherein said use helps restore liver function to normal.
In still another embodiment of the present invention, wherein dosage of said composition is ranging between 50-250 mg/kg.
In still another embodiment of the present invention, wherein said use is used for hepatocurative effect against drugs causing liver dysfunction, including anti-TB drugs. hi further embodiment of the present invention, the applicants provide protection against hepatotoxicity produced by all drugs, which are bio-activated by multiple CYP isoforms as indicated by clinical parameters in serum/hver. Besides, we claim that the clinical parameters showing toxicity are reversed even if the symptoms of genotoxicity may not begin to appear. For
example decrease in abnormal rise of serum Bilirubin, which may be attributed to a protective effect also due to other cellular factors such as membrane stabilization, as revealed in primary monolayer cultures of liver cells.
Further, applicants have made use of their expertise and years to research to establish that Emblica Officinalis (Alma) cures hepatotoxicity induced by drugs that is restricted to CYP 450 bio- activation hepatotoxicity.
Thus, applicants claim preparations from Emblica officinalis which are superior so far as their systemic effects are manifested in clinical profile (serum/liver parameters) which correlate to their hepatoprotective profile. hi further embodiment of the present invention, it relates to preparations and uses of preparation and use of such products which restores the normal liver function against drug induced toxicity as a result of bio-activation of drugs applicable with particular relevance to anti-TB drug(s) induced liver toxicity. The compositions and methods of the present invention increase biological defence mechanism of the tissue, improve recovery from dysfunctional states of the liver after prolonged challenge of anti-TB drugs.
In another embodiment of the present invention, the compositions and use of the present invention contain one of the extracts/ fractions of Emblica officinalis fruit as an essential ingredient. These extracts/ fractions may be obtained from fresh or semi dried fruits of Emblica officinalis. The compositions are formulated with more than one extracts and combined in any weight ratios. The preferred weight ratios include 1:1,1:2,1:1:1:, 1:2:2.2:1:2:, 2:2:1.
In still another embodiment of the present invention, it is related to preparation and use of products from Emblica officinalis, which restores normal liver function against drug induced toxicity caused as a result of bio-activation of drugs applicable with particular relevance to anti-TB drug(s) induced liver toxicity. The products of the invention comprise aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents extracts/ fractions from Emblica officinalis, obtained either from fresh or semi-dried fruits. These contain 8.5 -15 % of tannin content. It also relates to preparation of compositions of such products in different proportions of more than one ingredient. These products either alone or in combination are intended to be used against drug induced liver toxicity as represented by specific mechanism underlying liver disorders and usually manifested in clinical conditions of liver dysfunction.
In still another embodiment of the present invention, the preparations either alone or in composition are also intended to be used against anti-TB drug (s).The use of such products as developed in the present invention controls the abnormal rise in clinical pathological symptoms revealed by serum/ liver markers serving as indices of hepatic damage besides control of high levels of Bilirubin.
In still another embodiment of the present invention, in the development of the present invention the ample information has been utilized which exists regarding the advances in our understanding of mechanisms responsible for hepatotoxic injury due to drugs. More importantly the choice of a suitable model for the evaluation of anti-toxic profile of any substance is also crucial.
In still another embodiment of the present invention, a large body of information has been gained in favor of the present invention by using liver cell (hepatocyte) cultures, which ideally provide an insight into the mechanism of a toxin-induced impairment of hepato-biliary dysfunction because this model allows use of a test compounds (such as anti-TB drugs) to be used at cytotoxic level so that a valid and reproducible toxicity is generated. The in vitro cell culture model is of significant interest in ascertaining the mechanisms of toxicity and its reversal by protective agents.
In still another embodiment of the present invention, liver cells are considered as system of choice which have found ample application in the evaluation of cyto- cum geno-toxicity of chemicals and drugs (Nakagawa and Tayama, Arch Toxicol, 1995:69:208) and as such have been used in the evaluation of hepatoprotective profiles of the present invention. The mechanisms are revealed in critical biochemical functions of liver cells which are sensitive indicators of drug (s) toxicity. (Tomasi et al, Toxicol /Ntf/zo/: 15: 178-183). Both cellular lysis (measured by leakage of transaminases enzymes and lactated dehydrogenase from the cells) and the metabolic competence of the tissue are modified as a function of both the duration and concentration of the drugs (Goethals etalFundmAppl Toxicol 1984:4:441-450).
In still another embodiment of the present invention, the preparations (alone or in combination) act in a specific manner. These act against toxicity produced by drugs including anti-TB drugs which require bioactivation by hepatic cytochrome P 450 dependent mixed function oxidases. Cytochrome P450 have been shown to be involved in the liver toxicity (Anundi I, Lindros KO, Pharmacol Toxicol 1992; 70;453-458). Participation of CYP 450 dependent oxidation of drugs including anti-tubercular drugs rifampicin, isoniazid, pyrazinamide in liver is reported ( Ono et al, Biol Pharm Bull 1998:21 :421-425).
In still another embodiment of the present invention, that the preparations mentioned in the present invention act in a specific manner is further evidenced by the observation that these preparations have not been found effective against galactosamine induced toxicity which is not dependent upon the intervention of mixed function oxidases. Of serious concern is the toxicity produced by use of some drugs in combination such as anti-tubercular dmgs. Preparations alone or in combination, prevent not only (a) rifampicin (b) isoniazid (c) pyrazinamide induced toxicity but also various combinations of these such as (a) rifampicin + isoniazid (b) rifampicin + pyrazinamide (c) isoniazid + pyrazinamide and (d) rifampicin + isoniazid + pyrazinamide toxicity. The metabolic activation of drugs including anti-TB drugs alone or in combination is also accompanied by reactive intermediates which may be free radical/ active metabolites/ free oxy radicals through a variety of cellular oxidative metabolic pathways. An altered oxidative/ antioxidative profile is closely associated with production of drug (s) induced hepatic injury (Sodhi et al, Hum Exp Toxicol 1997; 16;315-321). The efficacy of the products of the present invention is further shown by their anti-lipoperoxidant (anti-oxidant) profile. By using the preparations of the present invention a decrease in the accumulation of excess levels of the product of oxygen metabolism has been revealed.
In still another embodiment of the present invention, also included are the preventing role of the products developed herein, against cell membrane leakage and restoration of cell viability in challenged liver tissues caused as a result of toxic menifestations. Preparations act in a specific manner in as much as they prevent toxicity produced by bioactivation of drug (s) and combination of drugs (s) as described in the above art. The products described have no cytotoxicity and on the other hand enhance overall biological defense systems per se.
Brief description of the accompanying drawings Figure 1 shows liver toxicity wherein plant extract attenuates Rifampicin induced hepatotoxicity by restoring liver function to normal (95% effect). The cell toxicity indicators shown in the said Fig. 1 is the leakage of lactate dehydrogenase (LDH) from intact cells after toxin challenge and its reversal by extracts.
Figure 2 shows leakage of glutamate pyruvate transaminase wherein said plant extracts in combination attenuates Rifampicin + isoniazid induced hepatotoxicity by restoring liver function to normal (96%). The cell toxicity indicators shown in Fig 2 is the leakage of glutamate pyruvate transaminase (GPT) from intact cells after toxin challenge and its reversal by the extracts in combination. (Model: primary monolayer cultures of liver cells).
Figure 3 shows leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by Emblica officinalis fraction wherein Emblica officinalis reverses Rifampicin + isoniazid +pyrazinamide induced hepatotoxicity and restores the liver function to normal
(96%). The cell toxicity indicators shown in Fig 3 is the leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by Emblica officinalis fraction.
Figure 4 shows protection against cell leakage wherein, Emblica officinalis fractions in combination prevents Rifampicin + isoniazid induced toxicity. Fig. 4 shows that fractions provide 96% protection against cell leakage as measured by serum GPT levels and increases cellular defense. 75% increase in glutathione levels (liver) is observed. Figure 5 shows Emblica officinalis extract reverses Rifampicin + isoniazid + pyrazinamide induced toxicity. Fig 5 shows 94 % protection against rise in lipid Peroxidation
(LPO, liver) and 96% decrease of serum Bilirubin in response to treatment with extract of the present invention.
Figure 6 shows a flow chart for the preparation of extract from fruit Emblica Officinalis. Examples
The invention of instant Application is further illustrated by the following examples, which should not, however be construed to limit the scope of the invention. The following examples are not intended to be limiting in any way, but demonstrate some of the preferred embodiments of the present invention. Any person skilled in the art can design more combinations useful against drug-induced toxicity, which may be considered as part of the present invention. Example 1.
Table 1 shows that the plant products are effective against paracetamol hepatotoxicity which is mainly dependent against bioactivation mechanisms mediated by CYP 450. % protection is shown as combined effect release of LDH and GPT in serum.
Table 1: Effect of plant products against hepatotoxicity produced by paracetamol
Treatment paracetamol
Toxicity 93% % protection as measured by combined effect against LDH and GPT leakage
Extract 97%protection
Fraction 96 % protection
Example 2.
Table 2 shows that the preparations of the present invention are not effective against liver toxicity produced by agents where the toxicity is primarily not dependent on bioactivation by
CYP 450.
Table 2: Effect of plant products against hepatotoxicity produced by galactosamine.
Treatment galactosamine
Toxicity 93%
% protection as measured by combined effect against LDH and GPT leakage
Extract 3%
Fraction 7 %
Example 3.
Plant extract attenuates Rifampicin induced hepatotoxicity by restoring liver function to normal (95% effect). The cell toxicity indicators shown in Fig. 1 is the leakage of lactate dehydrogenase (LDH) from intact cells after toxin challenge and its reversal by extracts. (Model; primary monolayer cultures of liver cells)
Example 4.
Plant extracts in combination attenuates Rifampicin + isoniazid induced hepatotoxicity by restoring liver function to normal (96%). The cell toxicity indicators shown in Fig 2 is the leakage of glutamate pyruvate tiansaminase (GPT) from intact cells after toxin challenge and its reversal by the extracts in combination. (Model: primary monolayer cultures of liver cells).
Example 5.
Emblica officinalis reverses Rifampicin + isoniazid +pyrazinamide induced hepatotoxicity and restores the liver function to normal (96%). The cell toxicity indicators shown in Fig 3 is the leakage of serum glutamate pyruvate transminase (GPT) after toxin challenge and its reversal by
Emblica officinalis fraction.
Example 6.
Emblica officinalis fractions in combination prevents Rifampicin + isoniazid induced toxicity. Fig. 4 shows that fractions provide 96% protection against cell leakage as measured by serum GPT levels and increases cellular defense. 75% increase in glutathione levels (liver) is observed.
Example 7.
Emblica officinalis extract reverses Rifampicin + isoniazid + pyrazinamide induced toxicity. Fig 5 shows 94 % protection against rise in lipid Peroxidation (LPO, liver) and 96% decrease of serum Bilirubin in response to treatment with extract of the present invention.
Claims
1. A composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives.
2. A composition as claimed in claim 1, wherein said additives are selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and/or pharmaceutically acceptable carrier, excipient, diluent, or solvent.
3. A composition as claimed in claim 1, wherein said composition is administered orally.
4. A composition as claimed in claim 1, wherein said extract and additives are in the ratio ranging between 1 : 1 to 1 : 10.
5. A composition as claimed in claim 1, wherein said additives have no effect on the hepatocurative effect of the said extract.
6. A composition as claimed in claim 1, wherein said extract is prepared in a solvent selected from a group comprising aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents.
7. A composition as claimed in claim 1, wherein said composition shows tanin content in the range of 8.5 to 15%.
8. A composition as claimed in claim 1, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
9. A use of preparing composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives, said use comprising steps of adding polar solvent to the fruit Emblica Officinalis to obtain the extract and optionally adding pharmaceutically acceptable additives.
10. A use as claimed in claim 9, wherein said fruit is incubated with polar solvent at room temperature for about 15-25 hours.
11. A use as claimed in claim 9, wherein said extract is from fresh and/or semi dried fruits of Emblica Officinalis.
12. A use as claimed in claim 9, wherein said extract and additives are in the ratio ranging between 1:1 to 1:10.
13. A use as claimed in claim 9, wherein said extract is prepared in a solvent selected from a group comprising aqueous, aqueous-ethanolic, ethanolic, ketonic, ethereal, halogenated solvents.
14. A use as claimed in claim 9, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
15. A use of composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives for treating a subject for CYP 450 and free radical mediated hepatotoxicity caused by drugs, said use comprising steps of:
(a) introducing drug toxicity in hepatocytes, (b) adding said composition to said hepatocytes exposed to drug hepatotoxicity,
(c) measuring changes in the level of liver/serum markers to estimate hepatocurative effect of the said composition.
16. A use as claimed in claim 15, wherein said use is particularly effective against hepatotoxicity caused by anti-TB drugs.
17. A use as claimed in claim 15, wherein said composition is not effective against hepatotoxicity which is independent of bio-activation by CYP 450.
18. A use as claimed in claim 15, wherein said composition is administered orally.
19. A use as claimed in claim 15, wherein, said composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.
20. A use as claimed in claim 15, wherein said composition is useful for treating animals or human beings.
21. A use as claimed in claim 15, wherein said composition has no adverse effect on health.
22. A use as claimed in claim 15, wherein said drugs are selected from a group comprising Paracetamol, CC14, and anti-TB drugs.
23. A use as claimed in claim 22, wherein said anti-TB drags are selected from a group comprising Rifampicin, Pyrazinamide, and isoniazid.
24. A use as claimed in claim 15, wherein said composition controls abnormal rise in the clinical pathological symptoms revealed by serum liver markers serving as indices of hepatic damage besides control of high levels of Bilirubin.
25. A use as claimed in claim 15, wherein said uses hepatocyte culture for ideal insight.
26. A use as claimed in claim 15, wherein said drugs is used at cytotoxic levels to produce valid and reproducible results in liver cells.
27. A use as claimed in claiml5, wherein said composition is useful for treating animals or human beings.
28. A use as claimed in claim 15, wherein said composition has no adverse effect on health.
29. A use as claimed in claim 15, wherein said composition shows restoration of hepatocyte viability.
30. A use as claimed in claim 15, wherein said use shows prevention of cell membrane leakage.
31. A use as claimed in claim 15, wherein said composition shows about 96% hepatocurative effect against combined effect of anti-TB drugs of Rifampicin, and Isoniazid.
32. A use as claimed in claim 15, wherein said composition reverses the leakage of glutamate pyruvate transaminase (GPT) from hepatocyte.
33. A use as claimed in claim 15, wherein said composition shows hepatocurative effect of about 96%> against combined effect of anti-TB drugs of Rifampicin, isoniazid, and pyrazinamide.
34. A use as claimed in claim 15, wherein said composition shows about 94% hepatocurative effect against rise in lipid Peroxidation (LPO) induced by combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
35. A use as claimed as claim 15, wherein said composition shows about 96% decrease of serum Bilirubin as a hepatocurative effect against combination of anti-TB drugs Rifampicin, isoniazid, and pyrazinamide.
36. A use as claimed in claim 15, wherein said use helps restore liver function to normal.
37. A use as claimed in claim 15, wherein dosage of said composition is ranging between 50-250 mg/kg.
38. A use as claimed in claim 15, wherein said use is used for hepatocurative effect against drugs causing liver dysfunction, including anti-TB drugs.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2002/000635 WO2003080090A1 (en) | 2002-03-26 | 2002-03-26 | Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1490078A1 true EP1490078A1 (en) | 2004-12-29 |
Family
ID=28053137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02716955A Withdrawn EP1490078A1 (en) | 2002-03-26 | 2002-03-26 | Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1490078A1 (en) |
| JP (1) | JP2005526792A (en) |
| KR (1) | KR20040101374A (en) |
| CN (1) | CN1627955A (en) |
| AU (1) | AU2002247880A1 (en) |
| CA (1) | CA2480334A1 (en) |
| WO (1) | WO2003080090A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638585A4 (en) | 2003-03-03 | 2009-07-22 | Benny Antony | A process and technique to elevate serum high density liboprotein |
| CN100381434C (en) * | 2005-08-22 | 2008-04-16 | 广西中医学院 | Production method of traditional Chinese medicine preparation of emblica extract with anticancer and antibacterial effects |
| WO2009153131A1 (en) * | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver enzyme induction |
| WO2009153136A2 (en) * | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver toxicity |
| US20120107432A1 (en) * | 2009-06-29 | 2012-05-03 | Benny Antony | Composition of extract of emblica officinalis and method of preparing the same |
| IN2013CH04565A (en) | 2013-10-08 | 2015-09-25 | Benny Antony | |
| US10286022B2 (en) | 2013-10-08 | 2019-05-14 | Benny Antony | Medicinal composition of extract of seed of emblica officinalis and method of preparing the same |
| CN103772452A (en) * | 2014-01-08 | 2014-05-07 | 合肥康龄养生科技有限公司 | Method for extracting tannin from phyllanthus emblica |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1028549A (en) * | 1996-07-12 | 1998-02-03 | Inahata Koryo Kk | Antiallergic and antiinflammatory food |
-
2002
- 2002-03-26 KR KR10-2004-7015457A patent/KR20040101374A/en not_active Ceased
- 2002-03-26 JP JP2003577916A patent/JP2005526792A/en active Pending
- 2002-03-26 CA CA002480334A patent/CA2480334A1/en not_active Abandoned
- 2002-03-26 EP EP02716955A patent/EP1490078A1/en not_active Withdrawn
- 2002-03-26 CN CNA028290305A patent/CN1627955A/en active Pending
- 2002-03-26 WO PCT/IB2002/000635 patent/WO2003080090A1/en not_active Ceased
- 2002-03-26 AU AU2002247880A patent/AU2002247880A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1028549A (en) * | 1996-07-12 | 1998-02-03 | Inahata Koryo Kk | Antiallergic and antiinflammatory food |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE WPI Section Ch Week 199815, Derwent World Patents Index; Class B04, AN 1998-162497 * |
| DOTY S.L. ET AL: "Enhanced metabolism of halogenated hydrocarbons in transgenic plants containing mammalian cytochrome P450 2E1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 12, 2000, pages 6287 - 6291 * |
| See also references of WO03080090A1 * |
| YAMAZAKI H. ET AL: "Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009)", CARCINOGENESIS, vol. 13, no. 6, 1992, pages 979 - 985, XP009089415 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002247880A1 (en) | 2003-10-08 |
| JP2005526792A (en) | 2005-09-08 |
| CA2480334A1 (en) | 2003-10-02 |
| KR20040101374A (en) | 2004-12-02 |
| CN1627955A (en) | 2005-06-15 |
| WO2003080090A1 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080138452A1 (en) | Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs | |
| Lee et al. | The pharmacological potential of Phyllanthus niruri | |
| Elekofehinti et al. | Hypoglycemic, antiperoxidative and antihyperlipidemic effects of saponins from Solanum anguivi Lam. fruits in alloxan-induced diabetic rats | |
| US9011938B2 (en) | Methods and formulations for treating chronic liver disease | |
| Singab et al. | Antioxidant and hepatoprotective activities of Egyptian moraceous plants against carbon tetrachloride-induced oxidative stress and liver damage in rats | |
| Kavitha et al. | Phytochemical analysis and hepatoprotective properties of Tinospora cordifolia against carbon tetrachloride-induced hepatic damage in rats | |
| Xia et al. | Hepatoprotective activity of puerarin against carbon tetrachloride-induced injuries in rats: a randomized controlled trial | |
| Tunna et al. | Weeds as alternative useful medicinal source: Mimosa pudica Linn. on diabetes mellitus and its complications | |
| Okoli et al. | Antioxidant and hepatoprotective activity of fruit extracts of Tetrapleura tetraptera (Schum & Thonn) Taubert | |
| EP1490078A1 (en) | Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450 | |
| Asir et al. | Antidiabetic activity of aqueous and ethanolic extracts of Passiflora foetida L. in alloxan induced diabetes rats | |
| Sangare et al. | Evaluation of the hepatoprotective activity of Gomphrena celosioides (Amaranthaceae) on Wistar rats intoxicated with tetrachloride carbon | |
| Aja et al. | Hepato-protective effect of ethanol extract of Pterocarpus santalinoides leaf on carbon tetrachloride (CCl4) induced albino rats | |
| El-Dashlouty et al. | Fighting hepatotoxication with CCl4 of male albino rats using plant flowers | |
| EP1207894B1 (en) | Use of a synergistic composition for the manufacture of a medicament for the treatment of liver associated ailments | |
| Thanigavelan et al. | An overview of the Herbs in a Siddha Polyherbal decoction-Pidangunaari Kudineer indicated for Hepatomegaly | |
| Faye et al. | Antidiabetic activity of 40 plants of the senegalese flora, an important therapeutic diversity for populations | |
| Bakr | Nymphaea alba and Liver Protection | |
| Egbuna et al. | Antihepatotoxic effects of Ficus vogelii ethanol leaf extract on the liver function indices of CCl4-induced hepatotoxicity in rats | |
| US6733800B1 (en) | Synergistic composition for the treatment of liver and liver associated ailments and a process for preparing the same | |
| Abdelrahman | Hepatoprotective activity of ethanolic and ethyl acetate extracts of Sterculia Setigera against carbon tetrachloride induced hepatotoxicity in albino rats | |
| Cyril-Olutayo et al. | Effect of Momordica charantia L. Leaf Extract on Liver Function, Lipid Profile and Oxidative Status of Mice | |
| Ahmed et al. | Research Article GC-MS Phytochemical Profiling, Antidiabetic, and Antioxidant Activities of Khaya senegalensis Stem Bark and Azadirachta indica Leaves Extracts in Rats | |
| Obiekwe et al. | Prophylactic activities of Olax viridis in the liver of rats challenged with carbon tetrachloride | |
| Ekinya et al. | Hepato-Curative and Antioxidative Potentials of Ethanol and Hexane Fractions of Methanol Leaf-Extract of Annona muricata against Paracetamol-induced Hepatotoxicity in Albino Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041022 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17Q | First examination report despatched |
Effective date: 20050310 |
|
| APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
| APAI | Date of receipt of notice of appeal modified |
Free format text: ORIGINAL CODE: EPIDOSCNOA2E |
|
| APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
| APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
| APBD | Information on interlocutory revision deleted |
Free format text: ORIGINAL CODE: EPIDOSDIRAPE |
|
| APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
| APBV | Interlocutory revision of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNIRAPE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20121002 |